Navigation Links
Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant
Date:8/12/2010

Mount Sinai School of Medicine today announced that the National Institutes of Health (NIH) has renewed its funding of the Consortium of Food Allergy Research (CoFAR), providing an additional $29.9 million toward genetic research and the prevention and treatment of food allergy. Mount Sinai is the primary research site for CoFAR, leading seven other institutions around the country.

Under the renewed grant, Mount Sinai researchers will continue several clinical trials evaluating immunotherapies for peanut and egg allergy. In two of the studies, researchers are determining whether an extract of peanut protein under the tongue or ingesting increasing amounts of egg protein improves tolerance. In another trial, researchers administer gradually increased doses of peanut protein to patients in a suppository to treat the allergy. The Mount Sinai team will also initiate a new trial studying the use of a peanut protein patch applied to the skin to treat peanut allergy. CoFAR is also conducting an observational study that has enrolled more than 500 infants to determine what factors worsen or improve their allergies.

"We are excited about the progress we have made in understanding food allergy in children over the last five years," said Hugh Sampson, MD, Professor, Pediatrics, Chief, Division of Allergy & Immunology, Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine and lead investigator on CoFAR. "With the renewal of this grant, we will expand our research and hopefully move closer toward ending the widespread impact of food allergy."

The grant will also fund new genetic research on eosinophilic gastrointestinal diseases (EGIDs), a new group of allergic diseases. According to the NIH, the most common EGID is eosinophilic esophagitis. The main symptoms in children include nausea, vomiting, and abdominal pain after eating. Three new CoFAR trial sites at Cincinnati Children's Medical Center Hospital, University of Colorado at Denver, and Children's Hospital of Philadelphia will conduct the research.

Dr. Sampson will remain principal investigator of the five original CoFAR sites: The Mount Sinai Medical Center, Duke University Medical Center, Johns Hopkins University, National Jewish Health in Denver, and University of Arkansas for Medical Sciences. CoFAR is currently enrolling patients for the trials evaluating treatment with peanut protein administered orally and through the skin patch.

Funding for CoFAR is provided by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases, components of NIH.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
2. Chicago Father and Son Team to Climb Mount Kilimanjaro for ShelterBox
3. AAU Big Mountain Jam Basketball Tournament To Be Played On SnapSports Flooring
4. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
5. Women who consume large amounts of tea have increased risk of rheumatoid arthritis
6. Albeo Releases Six New Surface Mount LED Lighting Fixtures
7. Green Drinks NYC and Green Mountain Energy Company Present Summer Bash at Solar One
8. The Mount Sinai Hospital Ranked in Top 25 of Best Children's Hospitals in Two Specialties by U.S. News & World Report
9. Mount Sinai researchers approaching universal treatment for all strains of influenza
10. Mountain Retreat for Women Whose Lives Have Been Touched by Cancer
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ., the ... has been recognized as one of the best small businesses for new dads by ... of nine small businesses providing progressive benefits to new parents on the organization’s ...
(Date:5/27/2016)... ... , ... With over 60 percent of acute stroke survivors being left unable ... aid in the rehabilitation process has steadily increased. Ekso Bionics had been working to ... to stroke. , Ekso Bionics has now received clearance from the U.S. Food and ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities ... within the industry, from leading advocates, associations and industry leaders such as Bioness. ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Beleza Medspa ... body fat composition regulations. This is the first time that Coolsculpting is being ... at least every six months to ensure they meet the prescribed body-fat standard, measured ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/25/2016)... , May 25, 2016 ... 2016"market research report that provides an overview on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ... reviews key players involved in the therapeutic development ...
(Date:5/24/2016)... 24, 2016 Cirujanos holandeses han ... a los médicos a compartir sus mejores prácticas por ... mundial. Profesionales médicos de Europa, África, Asia ... a la aplicación, que combina la transmisión en vivo ... seguro. Educación   "Imagine un médico ...
Breaking Medicine Technology: